A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1

A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1

Selective free fatty acid receptor 1 (FFAR1)/GPR40 agonist fasiglifam (TAK-875), an antidiabetic drug under phase 3 development, potentiates insulin secretion in a glucose-dependent manner by activating FFAR1 expressed in pancreatic β cells. Although fasiglifam significantly improved glycemic contro...

Full description

Bibliographic Details
Main Authors: Yabuki, Chiori, Komatsu, Hidetoshi, Tsujihata, Yoshiyuki, Maeda, Risa, Ito, Ryo, Matsuda-Nagasumi, Kae, Sakuma, Kensuke, Miyawaki, Kazumasa, Kikuchi, Naoya, Takeuchi, Koji, Habata, Yugo, Mori, Masaaki
Format: Online
Language:English
Published: Public Library of Science 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794927/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794927/

Similar Items